This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pharmaceuticals: Archive
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed
by Zacks Equity Research
Pfizer shares fall after CFO Dave Denton announces his exit, though the company reaffirms 2026 guidance and maintains its strategic outlook.
PFENegative Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs medical pharmaceuticals vaccines
Denali to Sell Priority Review Voucher for $195M Cash Boost
by Zacks Equity Research
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
SNYNegative Net Change BIIBNegative Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Vertex's Kidney Pipeline Power Its Next Growth Phase?
by Kinjel Shah
VRTX is betting on kidney disease candidates like povetacicept and inaxaplin to drive long-term growth beyond its dominant cystic fibrosis franchise.
VRTXNegative Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
pharmaceuticals
J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?
by Kinjel Shah
J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
JNJNegative Net Change AMGNNegative Net Change TEVANegative Net Change PTGXPositive Net Change
pharmaceuticals
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
by Zacks Equity Research
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
MRNAPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Top Research Reports for Alphabet, Broadcom & Johnson & Johnson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Broadcom Inc. (AVGO) and Johnson & Johnson (JNJ), as well as two micro-cap stocks, Franklin Wireless Corp. (FKWL) and Park Aerospace Corp. (PKE).
CNegative Net Change CMENegative Net Change JNJNegative Net Change PLDNegative Net Change AVGOPositive Net Change GOOGLPositive Net Change
internet pharmaceuticals semiconductor
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
by Zacks Equity Research
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
RHHBYNegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
by Zacks Equity Research
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
JAZZNegative Net Change LQDAPositive Net Change ABCLPositive Net Change IMCRPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space?
by Kinjel Shah
PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.
AZNNegative Net Change PFENegative Net Change NVONegative Net Change LLYNegative Net Change
pharmaceuticals
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
by Ahan Chakraborty
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals